A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07229313
Phase
PHASE1
Sponsor
Kivu Bioscience Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • KIVU-107
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Brisbane, Queensland, Australia|-27.46794,153.02809
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Male or female ≥18 years of age
  • No therapy of proven efficacy exists for the tumor
  • Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for …
  • Adequate bone marrow, kidney, and liver function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →